Comparison Of Allogeneic Hematopoietic Cell Transplantation Versus Chemotherapy In Patients With Acute Myeloid Leukemia In First Remission

Objective:To compare the effiency and safety of allogeneic hematopoietic stem cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remissionMethods:Clinical data of225patients who were diagnosed AML between Jan1st2006to Dec312011, getting CR1after chemotherapy, of which77patients received allogeneic stem cell transplantation after CR1(SCT group) and148patients still received chemotherapy(CTx group).Follow up to Dec312012,we evaluate the RFS and OS between SCT and CTx groupResults:Median follow up time:SCT34.00months; CTx25.50months.The median CR period(months):SCT33.00vs CTx22.50(p<0.01);3y OS:SCT75.8%vs CTx55.8%(p<0.001), both in intermediate and unfavourable karyotype group. SCT is better than CTx with statistical significance.3y RFS:SCT72.7%vs CTx44.8%(p<0.001),both in intermediate and unfavourable karyotype group. SCT is better than CTx with statistical significance. Among the148patients in CTx group.79died by the end of the follow up time,of which31died of TRM.In the SCT group, the TRM rate was11/18,the TRM rate has no statistical significance between the two groups.Conclusions:Allogeneic hematopoietic stem cell transplantation is safe and effective for AML-CR1patients who are categorized into the intermediate or unfavourable group according to the SWOG criteria.